Cablivi
What Cablivi is used for
Cablivi is indicated for the treatment of adults experiencing an episode of acquired thrombotic thrombocytopenic purpura (aTTP), in conjunction with plasma exchange and immunosuppression.
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
Key facts
- Brand
- Cablivi
- Active substance
- caplacizumab
- Disease area
- Purpura, Thrombotic Thrombocytopenic
- Medicine group
- Antithrombotic agents
- ATC code
- B01A
- Marketing authorisation holder
- Ablynx NV
- Authorised in the EU since
- 2018
Official information
In the USA
Same active substance: Cablivi
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Cablivi used for?
Cablivi is indicated for the treatment of adults experiencing an episode of acquired thrombotic thrombocytopenic purpura (aTTP), in conjunction with plasma exchange and immunosuppression.
What is the active substance in Cablivi?
Cablivi contains caplacizumab.
Who makes Cablivi?
The EU marketing authorisation holder is Ablynx NV.
Is Cablivi an orphan medicine?
Yes. Cablivi is designated an orphan medicine in the EU, for a rare disease (Purpura, Thrombotic Thrombocytopenic).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU